Khanyukov O. O., Pisotska L. A., Sapozhnychenko L. V., Pampukha O. O., Valchuk D. S.

LITERATURE REVIEWS

Scentific article

Abstract. Background. Anemia and iron deficiency are common comorbid conditions of patients with chronic heart failure (CHF). However, the issue of studying existing and developing new areas of treatment of anemia and iron deficiency in this category of patients still remains relevant. Aim. Review literature illustrating current data about treatment directions of anemia and iron deficiency in patients with CHF. Results. Treatment of anemia requires determination of its etiology and correction according to the cause, but a fairly common problem of establishing the etiology causes the complexity of subsequent treatment. Nowadays, the most reasonable approach to the treatment of iron deficiency and anemia for patients with CHF, taking into account current evidence (the results of randomized clinical trials) should be considered the intravenous use of iron carboxymaltose. In patients with CHF, treatment of severe anemia in the acute phase includes blood transfusion. The use of erythropoietin stimulants is not recommended for patients with CHF with anemia and/or iron deficiency. Oral iron therapy, which is often used as first-line therapy for iron deficiency for patients with CHF, does not have sufficient clinical data to support its efficacy. Promising areas that may be recommended after all the necessary clinical trials – the use of sugary iron, which is an innovative oral drug, drugs targeted to hepcidin. Conclusions. Patients with CHF, iron deficiency and anemia negatively affect functional ability, and are accompanied by an increase in hospitalizations and mortality. The development of new directions in the treatment of anemia and iron deficiency is becoming important in the context of treatment of patients with CHF, because the correction of these pathological conditions can reduce the clinical manifestations of CHF and improve the prognosis in this category of patients.

anemia, iron deficiency, chronic heart failure, treatment directions.

1. Gonzalez-Costello J, Cainzos-Achirica M, Lupón J, Farré N, Moliner-Borja P, Enjuanes C, et al. Use of intravenous iron in patients with iron deficiency and chronic heart failure: Real-world evidence. Eur J Intern Med [Internet]. 2020;80(March):91-8. Available from: https:// doi.org/10.1016/j.ejim. 2020.04.031.
2. Kotecha D, Ngo K, Walters JAE, Manzano L, Palazzuoli A, Flather MD. Erythropoietin as a treatment of anemia in heart failure: Systematic review of randomized trials. Am Heart J [Internet]. 2011;161(5):822-831. Available from: http://dx.doi.org/10.1016/j.ahj.2011.02.013.
3. Swedberg K, Young JB, Anand IS, Cheng S, Desai AS, Diaz R, et al. Treatment of Anemia with Darbepoetin Alfa in Systolic Heart Failure. N Engl J Med. 2013;368(13):1210-9.
4. Ponikowski P, Van Veldhuisen DJ, Comin-Colet J, Ertl G, Komajda M, Mareev V, et al. Beneficial effects of long-term intravenous iron therapy with ferric carboxymaltose in patients with symptomatic heart failure and iron deficiency. Eur Heart J. 2015;36(11):657-68.
5. Anker SD, Comin Colet J, Filippatos G, Willenheimer R, Dickstein K, Drexler H, et al. Ferric Carboxymaltose in Patients with Heart Failure and Iron Deficiency. N Engl J Med. 2009;361(25):2436-48.
6. Jankowska EA, Suchocki T, Tkaczyszyn M, Von Haehling S, Doehner W, Banasiak W, et al. Effects of Intravenous Iron Therapy in Iron Deficient Patients With Systolic Heart Failure: Meta-Analysis of Randomized Control Trials. J Am Coll Cardiol. 2015;65(10):A854.
7. Walther CP, Triozzi JL, Deswal A. Iron deficiency and iron therapy in heart failure and chronic kidney disease. Curr Opin Nephrol Hypertens. 2020;29(5):508-14.
8. McDonagh T, Damy T, Doehner W, Lam CSP, Sindone A, van der Meer P, et al. Screening, diagnosis and treatment of iron deficiency in chronic heart failure: putting the 2016 European Society of Cardiology heart failure guidelines into clinical practice. Eur J Heart Fail. 2018;20(12):1664-72.
9. Punj S, Ghafourian K, Ardehali H. Iron deficiency and supplementation in heart failure and chronic kidney disease. Mol Aspects Med [Internet]. 2020;75(July):100873. Available from: https://doi.org/10.1016/j.mam. 2020.100873.
10. Lewis GD, Malhotra R, Hernandez AF, McNulty SE, Smith A, Felker GM, et al. Effect of Oral Iron Repletion on Exercise Capacity in Patients With Heart Failure With Reduced Ejection Fraction and Iron Deficiency: The IRONOUT HF Randomized Clinical Trial’, The Journal of the American medical assosiation. 2017 May 16;317(19):1958-1966. DOI: 10.1001/jama. 2017.5427
11. Van Veldhuisen DJ, Ponikowski P, Van Der Meer P, Metra M, Böhm M, Doletsky A, et al. Effect of Ferric Carboxymaltose on Exercise Capacity in Patients with Chronic Heart Failure and Iron Deficiency. Circulation. 2017;136(15):1374-83.
12. Ponikowski P, Kirwan BA, Anker SD, McDonagh T, Dorobantu M, Drozdz J, et al. Ferric carboxymaltose for iron deficiency at discharge after acute heart failure: a multicentre, double-blind, randomised, controlled trial. Lancet. 2020;396(10266):1895-904.
13. Toblli JE, Di Gennaro F, Rivas C. Changes in echocardiographic parameters in iron deficiency patients with heart failure and chronic kidney disease treated with intravenous iron. Hear Lung Circ [Internet]. 2015;24(7):686-95. Available from: http://dx.doi.org/10.1016/j. hlc.2014.12.161.
14. Okonko DO, Grzeslo A, Witkowski T, Mandal AKJ, Slater RM, Roughton M, et al. Effect of Intravenous Iron Sucrose on Exercise Tolerance in Anemic and Nonanemic Patients With Symptomatic Chronic Heart Failure and Iron Deficiency. FERRIC-HF: A Randomized, Controlled, Observer-Blinded Trial. J Am Coll Cardiol. 2008;51(2):103-12.
15. Jankowska EA, Wojtas K, Kasztura M, Mazur G, Butrym A, Kalicinska E, et al. Bone marrow iron depletion is common in patients with coronary artery disease. Int J Cardiol [Internet]. 2015;182(C):517-22. Available from: http://dx.doi.org/10.1016/j.ijcard.2014.10.006.
16. Beck-Da-Silva L, Piardi D, Soder S, Rohde LE, Pereira-Barretto AC, De Albuquerque D, et al. IRON-HF study: A randomized trial to assess the effects of iron in heart failure patients with anemia. Int J Cardiol [Internet]. 2013;168(4):3439–42. Available from: http://dx.doi. org/10.1016/j.ijcard. 2013.04.181.
17. Anker SD, Kirwan BA, van Veldhuisen DJ, Filippatos G, Comin-Colet J, Ruschitzka F, et al. Effects of ferric carboxymaltose on hospitalisations and mortality rates in iron-deficient heart failure patients: an individual patient data meta-analysis. Eur J Heart Fail. 2018;20(1):125-33.
18. Pope M, Kalra PR. Iron Deficiency in Heart Failure: to Treat or Not to Treat? Curr Treat Options Cardiovasc Med. 2018;20(8):65.
19. National Institutes of Health US. National Library of Medicine. Effect of IV iron in patients with heart failure with preserved ejection fraction [Internet]. USA: National Institutes of Health US. National Library of Medicine; 2020. Available from: https://clinicaltrials.gov/ct2/show/ NCT03074591?cond= Effect+of+IV+iron+in+patients+with+heart+failure+with+preserved+ejection+fraction.&draw=2&rank=1.
20. National Institutes of Health US. National Library of Medicine.Randomized placebo-controlled trial of FCM as treatment for heart failure with iron deficiency.[Internet]. USA: National Institutes of Health US. National Library of Medicine; 2020. Available from: https://clinicaltrials. gov/ct2/show/NCT03037931?cond=Randomized+placebo-controlled+trial+of+FCM+as+treatment+for+heart+failure+with+iron+deficienc y.&draw=2&rank=1.
21. National Institutes of Health US. National Library of Medicine. Intravenous iron in patients with systolic heart failure and iron deficiency to improve morbidity & mortality. [Internet]. USA: National Institutes of Health US. National Library of Medicine; 2020. Available from: https:// clinicaltrials.gov/ct2/show/NCT03036462?cond=Intravenous+iron+in+patients+with+systolic+heart+failure+and+iron+deficiency+to+impr ove+morbidity+%26+mortality&draw=2&rank=1.
22. National Institutes of Health US. National Library of Medicine. Intravenous iron treatment in patients with heart failure and iron deficiency: IRONMAN. [Internet]. USA: National Institutes of Health US. National Library of Medicine; 2020. Available from: https://clinicaltrials.gov/ ct2/show/ NCT02642562?cond=Intravenous+iron+treatment+in+patients+with+heart+failure+and+iron+deficiency%3A+IRONMAN&draw =2&rank=1.

«Bulletin of problems biology and medicine» Issue 4 (162), 2021 year, 70-76 pages, index UDK 616.12-008.46-036.1:616.155.194:612.393.4]-08

10.29254/2077-4214-2021-4-162-70-76